Search results
Results from the WOW.Com Content Network
A glycine reuptake inhibitor (GRI) is a type of drug which inhibits the reuptake of the neurotransmitter glycine by blocking one or more of the glycine transporters (GlyTs). ). Examples of GRIs include bitopertin (RG1678), iclepertin (BI-425809), ORG-24598, ORG-25935, ALX-5407, and sarcosine, which are selective GlyT1 blockers, and ORG-25435 and N-arachidonylglycine, which are selective GlyT2 blo
D-Phenylalanine (DPA, D-Phe; Deprenon, Sabiben, Sabiden) – enkephalinase inhibitor; Agomelatine (Valdoxan) – 5-HT 2C receptor antagonist and MT 1 and MT 2 receptor agonist; Brexanolone (allopregnanolone; Zulresso) – GABA A receptor positive allosteric modulator – approved for postpartum depression
Glycerophospholipids are derived from glycerol-3-phosphate in a de novo pathway. [3] The term glycerophospholipid signifies any derivative of glycerophosphoric acid that contains at least one O-acyl, or O-alkyl, or O-alk-1'-enyl residue attached to the glycerol moiety. [4] The phosphate group forms an ester linkage to the glycerol.
Tyrosine kinase inhibitor (TKI) with selective activity against RET, VEGFR-2 and EGFR: Medullary thyroid cancer. Diarrhoea, hypertension, QT interval prolongation, depression, electrolyte anomalies, hypothyroidism and GI perforation (uncommon). 2.3 mTOR inhibitors: Everolimus: PO: mTOR inhibitor.
Sotagliflozin (Inpefa) is a dual SGLT1/SGLT2 inhibitor approved by the US Food and Drug Administration (FDA) in May 2023, to reduce the risk of cardiovascular death, hospitalization for heart failure, and urgent heart failure visit in adults with heart failure or type 2 diabetes, chronic kidney disease, and other cardiovascular risk factors.
Antiglucocorticoid drugs are a class of medications that act to reduce the effects of glucocorticoids, primarily cortisol, in the body. [1] They include direct glucocorticoid receptor antagonists such as mifepristone and synthesis inhibitors such as metyrapone, ketoconazole, and aminoglutethimide. They are used to treat Cushing's syndrome. [2]
These drugs act as antagonists or inverse agonists of the 5-HT 2A, α 1-adrenergic, and H 1 receptors, as partial agonists of the 5-HT 1A receptor, [3] and as inhibitors of the transporters. mCPP is an antagonist of the 5-HT 2B receptor, an agonist of the 5-HT 1A, [3] 5-HT 2C, and 5-HT 3 receptors, [4] [5] and acts as a partial agonist of the ...
In cancer treatment, growth factor receptor inhibitors have been used to target cancer cells. [2] In cancer research, growth factor receptor inhibitors have been applied to protect normal cells selectively from the toxic side-effects of chemotherapy targeted against cancer cells. [5]